An injectable oncolytic hydrogel platform for in situ dendritic cell vaccination to boost antitumor immunity

Abstract

Dendritic cell (DC) vaccines hold significant promise in cancer therapy due to their ability to induce durable anti-tumor immune responses. However, traditional ex vivo DC vaccines face considerable challenges, including...

Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity

“…We next evaluated whether the nanocomposite induces immunogenic cell death (ICD) in tumor cells and examined the functional consequence on dendritic cell (DC) maturation. ICD is classically characterized by surface exposure of calreticulin (CRT), nuclear-to-extracellular release of HMGB1 [ 40 ]. These ICD-associated danger signals can promote antigen uptake and maturation of DCs, thereby facilitating the initiation of adaptive immune responses.…”

Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity

“…We next evaluated whether the nanocomposite induces immunogenic cell death (ICD) in tumor cells and examined the functional consequence on dendritic cell (DC) maturation. ICD is classically characterized by surface exposure of calreticulin (CRT), nuclear-to-extracellular release of HMGB1 [ 40 ]. These ICD-associated danger signals can promote antigen uptake and maturation of DCs, thereby facilitating the initiation of adaptive immune responses.…”

Bioengineered In Situ-Forming Hydrogels as Smart Drug Delivery Systems for Postoperative Breast Cancer Immunotherapy: From Material Innovation to Clinical Translation

“…The primary aim of cancer immunotherapy is to create lasting immune memory that prevents the recurrence of tumors. Kim et al designed a thermosensitive LC-Gel for the co-delivery of the oncolytic peptide LTX-315 and CCL21, which triggers the formation of splenic germinal centers and the generation of circulating CD44 + CD62L − effector memory T cells [ 102 ]. Ke et al improved this strategy by incorporating hemostatic hydrogels with nanoparticle-based drug delivery systems, effectively halting tumor regrowth in treated mice, with survival extending beyond 60 days, compared to 36 days in the control group [ 103 ].…”

A thermosensitive hydrogel achieves sustained co-delivery of two therapeutic agents with distinct properties for preventing aseptic loosening

“…40,41 In contrast, local administration provides an effective alternative by increasing the therapeutic effect while reducing off-target toxicity, making it particularly suitable for treating localized diseases like aseptic loosening. 42–45 Injectable thermosensitive hydrogel systems based on amphiphilic block copolymers, such as poly(ethylene glycol) (PEG)-polyester copolymers, 46–52 PEG-poly(amino acid) copolymers, 53–57 and poly(phosphazenes), 58–60 have emerged as favorable platforms for localized delivery. These systems exhibit free-flowing sols at low or ambient temperature, enabling facile encapsulation of therapeutic payloads through simple mixing procedures.…”

Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity

“…We next evaluated whether the nanocomposite induces immunogenic cell death (ICD) in tumor cells and examined the functional consequence on dendritic cell (DC) maturation. ICD is classically characterized by surface exposure of calreticulin (CRT), nuclear-to-extracellular release of HMGB1 [ 40 ]. These ICD-associated danger signals can promote antigen uptake and maturation of DCs, thereby facilitating the initiation of adaptive immune responses.…”

Bioengineered In Situ-Forming Hydrogels as Smart Drug Delivery Systems for Postoperative Breast Cancer Immunotherapy: From Material Innovation to Clinical Translation

“…The primary aim of cancer immunotherapy is to create lasting immune memory that prevents the recurrence of tumors. Kim et al designed a thermosensitive LC-Gel for the co-delivery of the oncolytic peptide LTX-315 and CCL21, which triggers the formation of splenic germinal centers and the generation of circulating CD44 + CD62L − effector memory T cells [ 102 ]. Ke et al improved this strategy by incorporating hemostatic hydrogels with nanoparticle-based drug delivery systems, effectively halting tumor regrowth in treated mice, with survival extending beyond 60 days, compared to 36 days in the control group [ 103 ].…”

A thermosensitive hydrogel achieves sustained co-delivery of two therapeutic agents with distinct properties for preventing aseptic loosening

“…40,41 In contrast, local administration provides an effective alternative by increasing the therapeutic effect while reducing off-target toxicity, making it particularly suitable for treating localized diseases like aseptic loosening. 42–45 Injectable thermosensitive hydrogel systems based on amphiphilic block copolymers, such as poly(ethylene glycol) (PEG)-polyester copolymers, 46–52 PEG-poly(amino acid) copolymers, 53–57 and poly(phosphazenes), 58–60 have emerged as favorable platforms for localized delivery. These systems exhibit free-flowing sols at low or ambient temperature, enabling facile encapsulation of therapeutic payloads through simple mixing procedures.…”

Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity

“…We next evaluated whether the nanocomposite induces immunogenic cell death (ICD) in tumor cells and examined the functional consequence on dendritic cell (DC) maturation. ICD is classically characterized by surface exposure of calreticulin (CRT), nuclear-to-extracellular release of HMGB1 [ 40 ]. These ICD-associated danger signals can promote antigen uptake and maturation of DCs, thereby facilitating the initiation of adaptive immune responses.…”

Bioengineered In Situ-Forming Hydrogels as Smart Drug Delivery Systems for Postoperative Breast Cancer Immunotherapy: From Material Innovation to Clinical Translation

“…The primary aim of cancer immunotherapy is to create lasting immune memory that prevents the recurrence of tumors. Kim et al designed a thermosensitive LC-Gel for the co-delivery of the oncolytic peptide LTX-315 and CCL21, which triggers the formation of splenic germinal centers and the generation of circulating CD44 + CD62L − effector memory T cells [ 102 ]. Ke et al improved this strategy by incorporating hemostatic hydrogels with nanoparticle-based drug delivery systems, effectively halting tumor regrowth in treated mice, with survival extending beyond 60 days, compared to 36 days in the control group [ 103 ].…”

A thermosensitive hydrogel achieves sustained co-delivery of two therapeutic agents with distinct properties for preventing aseptic loosening

“…40,41 In contrast, local administration provides an effective alternative by increasing the therapeutic effect while reducing off-target toxicity, making it particularly suitable for treating localized diseases like aseptic loosening. 42–45 Injectable thermosensitive hydrogel systems based on amphiphilic block copolymers, such as poly(ethylene glycol) (PEG)-polyester copolymers, 46–52 PEG-poly(amino acid) copolymers, 53–57 and poly(phosphazenes), 58–60 have emerged as favorable platforms for localized delivery. These systems exhibit free-flowing sols at low or ambient temperature, enabling facile encapsulation of therapeutic payloads through simple mixing procedures.…”